← Home ← Back to /biz/

Thread 60647591

8 posts 4 images 5 unique posters /biz/
Anonymous (ID: rGzMnzLg) No.60647591 [Report] >>60647649 >>60647663 >>60647701
ESPR
Esperion Therapeutics, maker of nexlizet and nexletol, the only statin alternatives in the market will receive a buyout offer for $10 Billion from a previously-established partnership between pharmaceutical giants Merck and Daiichi Sankyo
Anonymous (ID: 09YfSi5W) No.60647649 [Report]
>>60647591 (OP)
>buyout
You have any claim to substantiate that? Every biotech stock seems to be on its way to being bought out.
Anonymous (ID: osqFxJRc) No.60647663 [Report]
>>60647591 (OP)
post proof of your insider trading bullshit so we can proceed
Anonymous (ID: ccMM5HdZ) No.60647701 [Report]
>>60647591 (OP)
been in merck since before the doggy shots were released. I have just seen them going down.
Anonymous (ID: erCI/Xi+) No.60647893 [Report] >>60647913
Is this good? Price go to 10 billion? Or is this bad and investors lose all their money?
Anonymous (ID: 09YfSi5W) No.60647913 [Report] >>60648022
>>60647893
OP is claiming a 40x.
Anonymous (ID: erCI/Xi+) No.60648022 [Report] >>60648207
>>60647913
That's, just put 5k in.
Anonymous (ID: 09YfSi5W) No.60648207 [Report]
>>60648022
>That's, just put 5k in.
I have doubts. OP claims both Merck and Daiichi Sankyo have previously established partnerships, but there's no history of Merck ever doing such a thing, but Daiichi Sankyo has.

A half-truth, or half-lie?